NCT03746522Phase 3Completed

Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity

Study sponsor: Rhythm Pharmaceuticals, Inc. · RYTM

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2020-11-16Actual
Enrollment · participants52Actual
Source updated2023-12-01Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview